Palliative therapy

Extensive small cell lung cancer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

During the past two decades advances have been made in the systemic treatment of small cell lung cancer. Chemotherapy will produce objective responses in the majority of patients, yet few patients with extensive disease have prolonged survival. Combination regimens like cyclophosphamide/doxorubicin/vincristine, cisplatin/etoposide, and cisplatin/etoposide/ifosfamide have produced objective responses in 55% to 65% of patients. Recent clinical trials with single-agent chemotherapy suggest median lengths of survival that appear comparable to that obtained with combination therapy. Such approaches may be appropriate for elderly patients and will be evaluated in a prospective randomized trial. Ultimately, to provide the maximum palliative benefit for patients with extensive small cell lung cancer, the therapeutic benefit must be balanced against the costs of treatment (physical, psychological, and financial).

Original languageEnglish
Pages (from-to)40-44
Number of pages5
JournalSeminars in Oncology
Volume22
Issue numberSUPPL. 3
StatePublished - 1995

Fingerprint

Small Cell Lung Carcinoma
Palliative Care
Etoposide
Cisplatin
Drug Therapy
Ifosfamide
Survival
Vincristine
Health Care Costs
Doxorubicin
Cyclophosphamide
Therapeutics
Clinical Trials
Psychology

ASJC Scopus subject areas

  • Oncology

Cite this

Palliative therapy : Extensive small cell lung cancer. / Loehrer, Patrick.

In: Seminars in Oncology, Vol. 22, No. SUPPL. 3, 1995, p. 40-44.

Research output: Contribution to journalArticle

@article{bd0828ff005447e1b50537da589d2a83,
title = "Palliative therapy: Extensive small cell lung cancer",
abstract = "During the past two decades advances have been made in the systemic treatment of small cell lung cancer. Chemotherapy will produce objective responses in the majority of patients, yet few patients with extensive disease have prolonged survival. Combination regimens like cyclophosphamide/doxorubicin/vincristine, cisplatin/etoposide, and cisplatin/etoposide/ifosfamide have produced objective responses in 55{\%} to 65{\%} of patients. Recent clinical trials with single-agent chemotherapy suggest median lengths of survival that appear comparable to that obtained with combination therapy. Such approaches may be appropriate for elderly patients and will be evaluated in a prospective randomized trial. Ultimately, to provide the maximum palliative benefit for patients with extensive small cell lung cancer, the therapeutic benefit must be balanced against the costs of treatment (physical, psychological, and financial).",
author = "Patrick Loehrer",
year = "1995",
language = "English",
volume = "22",
pages = "40--44",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Palliative therapy

T2 - Extensive small cell lung cancer

AU - Loehrer, Patrick

PY - 1995

Y1 - 1995

N2 - During the past two decades advances have been made in the systemic treatment of small cell lung cancer. Chemotherapy will produce objective responses in the majority of patients, yet few patients with extensive disease have prolonged survival. Combination regimens like cyclophosphamide/doxorubicin/vincristine, cisplatin/etoposide, and cisplatin/etoposide/ifosfamide have produced objective responses in 55% to 65% of patients. Recent clinical trials with single-agent chemotherapy suggest median lengths of survival that appear comparable to that obtained with combination therapy. Such approaches may be appropriate for elderly patients and will be evaluated in a prospective randomized trial. Ultimately, to provide the maximum palliative benefit for patients with extensive small cell lung cancer, the therapeutic benefit must be balanced against the costs of treatment (physical, psychological, and financial).

AB - During the past two decades advances have been made in the systemic treatment of small cell lung cancer. Chemotherapy will produce objective responses in the majority of patients, yet few patients with extensive disease have prolonged survival. Combination regimens like cyclophosphamide/doxorubicin/vincristine, cisplatin/etoposide, and cisplatin/etoposide/ifosfamide have produced objective responses in 55% to 65% of patients. Recent clinical trials with single-agent chemotherapy suggest median lengths of survival that appear comparable to that obtained with combination therapy. Such approaches may be appropriate for elderly patients and will be evaluated in a prospective randomized trial. Ultimately, to provide the maximum palliative benefit for patients with extensive small cell lung cancer, the therapeutic benefit must be balanced against the costs of treatment (physical, psychological, and financial).

UR - http://www.scopus.com/inward/record.url?scp=0028922994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028922994&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 40

EP - 44

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 3

ER -